TYAN
25.2.2020 09:02:14 CET | Business Wire | Press release
TYAN® , an industry-leading server platform design manufacturer and a subsidiary of MiTAC Computing Technology Corporation, is exhibiting their latest embedded motherboards optimized for the intelligent edge to service a wide range of vertical markets including security, industrial automation, communication and networking at Embedded World 2020 from February 25th ~27th , booth 2-311 in Nuremberg, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200225005008/en/
“Based on the Intel® Xeon® E-2200 processor and 9th Generation Intel® Core™ i3/i5/i7 series processor, TYAN’s embedded motherboards demonstrate how standard-based platforms powered by robust processors efficiently meet the demands of data analytics at the IoT edge," said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. Hsu added, “With key features including compact form factors, a wide range of operating temperatures, and long product supply lifetime, our Tempest EX motherboards are the ideal choice to build up edge systems that can bridge compute, storage, and networking resources.”
TYAN’s embedded products provide 7-year supply lifecycle, wide operating temperature range of 0-55°C and optional EMC Class B certification on selected boards, which are highly required for most embedded IoT applications. The Tempest EX S5550-EX is equipped with up to four 1000Base-T LAN ports, three standard PCIe slots, eight SATA 6G ports, HD audio and display port interfaces in Micro-ATX form factor; the Tempest EX S5552-EX supports four 1000Base-T LAN ports, 8-port SAS 12G controller, four standard PCIe and an optional 32-bit legacy PCI slot in ATX form factor. Both S5550-EX and S5552-EX boards are well suited for industrial automation server applications. The Tempest EX S5555-EX with two display ports, one DVI-D port, and 7.1 channel high definition audio in Micro-ATX form factor is ideal for embedded workstation applications.
The Tempest EX S5557 features two 1000Base-T LAN ports, 12V DC power input and two display ports in Thin Mini-ITX form factor. The ultra-slim embedded motherboard is a perfect fit for IoT appliance deployment. Moreover, the Thunder CX GX38-B5550 is a 1U single-socket Intel Xeon E-2200 processor-based compact server for IoT and edge computing. Featuring up 4 DDR4 DIMM slots, up to 4 onboard GbE LAN ports, 1 PCIe x8 slot and two 3.5" internal SATA 6G drive bays within a 15” deep chassis, Thunder CX GX38-B5550 makes it a top choice for datacenters with space constraints.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200225005008/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202615.5.2026 13:38:00 CEST | Press release
All economic and financial indicators grew:Consolidated revenues of €645.0 million (€607.5 million in 2025);EBITDA of €112.0 million (€105.3 million in 2025);EBIT of €95.1 million (€88.7 million in 2025);Profit before tax amounts to €99.8 million (€86.9 million in 2025). Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover. EBIT, from January to March, was €95.1 million (€88.7 million in 2025) and is equal to 14.7% of the turnover. The profit before tax, from January to March, was €99.8 million (€86.9 million in 2025), equal to 15.5% of the turnover. The net financial position of
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 13:30:00 CEST | Press release
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press release
New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership e
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom